VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2021 | First-in-human results of CDK2/4/6 inhibition in breast and ovarian cancer

Timothy Yap, MBBS, PhD, FRCP, University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the results of a first-in-human Phase I/IIa dose-escalation/expansion study of the first-in-class CDK2/4/6 inhibtior PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer. In this study it was found that PF-3600 can be combined with endocrine therapy with a manageable safety profile and demonstrates promising preliminary antitumor activity in heavily pretreated patients. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter